Skip to content
Why Pharma Needs to Forge New Drug Pricing Models episode artwork

Apr 7, 2016 28 min

Why Pharma Needs to Forge New Drug Pricing Models

from The Bio Report Hosted by Levine Media Group

As pricing pressure grow on the pharmaceutical industry, a recent article in Invivo argues that drugmakers must look to a variety of new pricing models built around collaborations with payers and providers. Such an approach, the authors argue, would minimize conflicts between stakeholders, close the information gap about the real-world value of new drugs, and allow for a more evidence-based approach to pricing. We spoke to Susan Garfield, a principal in EY's Life Sciences Advisory Services practice and co-author of the Invivo article, about the need for new approaches to pricing, why the existing unit price approach is too one-dimensional, and what’s at stake for the industry if it fails to innovate new models.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Why Pharma Needs to Forge New Drug Pricing Models

0:00 28:34

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 28 minutes long.

When was this The Bio Report episode published?

This episode was published on April 7, 2016.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.